• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

XBiotech Inc. - Common Stock (NQ:XBIT)

2.020 +0.020 (+1.00%)
Delayed Quote Updated: 4:00 PM EDT, Oct 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 41,224
Open 2.030
Bid (Size) 2.020 (3,200)
Ask (Size) 2.030 (200)
Prev. Close 2.000
Today's Range 1.990 - 2.080
52wk Range 1.905 - 3.440
Shares Outstanding 30,436,964
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
October 19, 2026
From XBiotech Inc.
Via GlobeNewswire
News headline image
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
June 15, 2026
From XBiotech Inc.
Via GlobeNewswire

Performance

52-Week Range 41.3% below 52-week high
2.020
1.9152W Low 3.4452W High
1 Week 11.8% below 1-week high
1.911W Low 2.291W High

XBiotech Inc. - Common Stock (XBIT) traded between $1.91 and $3.44 over the past 52 weeks and last traded at $2.02, 41.3% below its 52-week high. Over the past week it ranged between $1.91 and $2.29.

Past 12 Months
-6.5%
-7.3%
-10.2%
-19.5%
-15.1%
-18.5%
1W -$0.14
1M -$0.16
3M -$0.23
6M -$0.49
YTD -$0.36
1Y -$0.46

XBIT was -18.5% over the past year, -19.5% over six months, -15.1% year to date, -6.5% in the last week.

12 Months vs Market
XBIT
-18.5%
DIA
+12.3%
SPY
+14.6%
QQQ
+17.3%
IWM
+11.1%

Over the past 12 months XBIT returned -18.5% versus DIA (Dow) +12.3%, SPY (S&P 500) +14.6%, QQQ (Nasdaq 100) +17.3% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.86× 3-mo avg
Today 41,224 3-mo avg 48.1K
1W
136.5K
1M
59.0K
3M
48.1K
6M
39.5K
YTD
39.9K
1Y
54.5K

XBIT most recently traded 41,224 shares against a 3-month average daily volume of 48.1K.

More News

Read More
News headline image
XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm
January 13, 2025
From The Schall Law Firm
Via Business Wire
News headline image
XBiotech Pauses Rheumatology program
December 23, 2024
From XBiotech Inc.
Via GlobeNewswire
News headline image
XBIT Stock Earnings: XBiotech Reported Results for Q2 2024 ↗
August 12, 2024
Via InvestorPlace
News headline image
XBIT Stock Earnings: XBiotech Reported Results for Q1 2024 ↗
May 13, 2024
Via InvestorPlace
News headline image
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday? ↗
June 18, 2024
Via Benzinga
News headline image
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
June 18, 2024
From XBiotech Inc.
Via GlobeNewswire
News headline image
XBIT Stock Earnings: XBiotech Reported Results for Q4 2023 ↗
March 18, 2024
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
January 22, 2024
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
October 20, 2022
Via Benzinga
News headline image
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
January 04, 2024
From XBiotech Inc.
Via GlobeNewswire
News headline image
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
November 14, 2023
From XBiotech Inc.
Via GlobeNewswire
News headline image
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
September 26, 2023
From XBiotech Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
September 05, 2023
Via Benzinga
News headline image
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
August 30, 2023
From XBiotech Inc.
Via GlobeNewswire
News headline image
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
August 08, 2023
From XBiotech Inc.
Via GlobeNewswire
News headline image
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
May 22, 2023
From XBiotech Inc.
Via GlobeNewswire
News headline image
Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
May 17, 2023
Via Benzinga
News headline image
Dow Jumps Over 100 Points; US Housing Starts Rise In April ↗
May 17, 2023
Via Benzinga
News headline image
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
May 17, 2023
From XBiotech Inc.
Via GlobeNewswire
News headline image
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
April 17, 2023
From XBiotech Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
November 28, 2022
Via Benzinga
News headline image
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer
October 13, 2022
From XBiotech Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
September 22, 2022
Via Benzinga

Frequently Asked Questions

Is XBiotech Inc. - Common Stock publicly traded?
Yes, XBiotech Inc. - Common Stock is publicly traded.
What exchange does XBiotech Inc. - Common Stock trade on?
XBiotech Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for XBiotech Inc. - Common Stock?
The ticker symbol for XBiotech Inc. - Common Stock is XBIT on the Nasdaq Stock Market
What is the current price of XBiotech Inc. - Common Stock?
The current price of XBiotech Inc. - Common Stock is 2.020
When was XBiotech Inc. - Common Stock last traded?
The last trade of XBiotech Inc. - Common Stock was at 10/20/26 04:00 PM ET
What is the market capitalization of XBiotech Inc. - Common Stock?
The market capitalization of XBiotech Inc. - Common Stock is 61.48M
How many shares of XBiotech Inc. - Common Stock are outstanding?
XBiotech Inc. - Common Stock has 61M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap